Bioxytran, Inc.

BIXT

US09075D1028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:39:08 2024-04-26 pm EDT			5-day change	1st Jan Change
0.12 ^USD	-11.11%		-9.43%	-20.00%

Apr. 19	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Bioxytran, Inc. announced that it has received $0.13 million in funding

March 12, 2023

On March 13, 2023, Bioxytran, Inc., closed the transaction. The company has received $130,000 in the transaction. The transaction included participation from 3 investors.

Latest news about Bioxytran, Inc.

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist	Mar. 06	CI
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19	Feb. 21	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M	23-08-24	CI
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients	23-08-08	CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
China metals export curbs lift shares in US producer MP Materials	23-07-05	RE
China rare earth curbs lift shares in U.S. producer MP Materials	23-07-05	RE
Bioxytran, Inc. announced that it expects to receive $0.5 million in funding from Triton Funds, LLC	23-06-07	CI
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Bioxytran, Inc. Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	23-04-19	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Bioxytran, Inc. Announces Positive Phase 2 Trial Results	23-03-29	CI
Bioxytran, Inc. announced that it has received $0.13 million in funding	23-03-12	CI
Bioxytran, Inc. Announces Vitro Testing At Foundation for Neglected Disease Research in Bangalore India	23-02-28	CI
Bioxytran, Inc. Receives Approval to Initiate Trials with Prolectin-I	23-02-06	CI
Bioxytran, Inc. Announces Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial	22-12-28	CI
Bioxytran Establishes Indian Subsidiary Pharmalectin India Private Limited in Preparation of Commercialization	22-12-14	CI
Bioxytran Receives Approval to Optimize Dosage in Covid-19 Patients	22-12-08	CI
Bioxytran, Inc. announced a financing transaction	22-11-27	CI
BIOXYTRAN, INC. Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print	22-11-16	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOXYTRAN, INC.	-20.00%	21M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B